正版西瓜太妹
Lv21
130 积分
2022-10-24 加入
-
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
9天前
已完结
-
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
18天前
已完结
-
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
18天前
已完结
-
Anti-obesity drug discovery: advances and challenges
18天前
已完结
-
Contemporary medical, device, and surgical therapies for obesity in adults
18天前
已完结
-
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
25天前
已完结
-
GLP-1 and Amylin in the Treatment of Obesity
25天前
已完结
-
GLP-1 and amylin receptor multiagonism with amycretin for obesity management
25天前
已完结
-
Can amylin-based drugs upstage GLP-1 agonists?
26天前
已完结
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
1个月前
已完结